Role of echocardiography in toxic heart valvulopathy

European Journal of Echocardiography

Volumn 10, Issue 4, 2009, Pages 467-476

  Droogmans, Steven ^a,b   Kerkhove, Dirk ^a   Cosyns, Bernard ^a,b   Van Camp, Guy ^a,b  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

Amphetamines; Anorexigens; Echocardiography; Ergot derived dopamine agonists; Toxic valvulopathy

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; BENFLUOREX; BROMOCRIPTINE; CABERGOLINE; DEXFENFLURAMINE; ERGOTAMINE; FENFLURAMINE; METHYLPHENIDATE; METHYSERGIDE; PERGOLIDE; PHENTERMINE; RILATIDE; SEROTONIN 2B RECEPTOR; UNCLASSIFIED DRUG;

AORTA VALVE REGURGITATION; ATTENTION DEFICIT DISORDER; CARDIOVASCULAR RISK; COLOR ULTRASOUND FLOWMETRY; DRUG USE; DYSPNEA; ECHOCARDIOGRAPHY; FATIGUE; HEART MURMUR; HEART PALPITATION; HISTOPATHOLOGY; HUMAN; LOW DRUG DOSE; MICROPHOTOGRAPHY; MITRAL VALVE; MITRAL VALVE REGURGITATION; MORPHOLOGY; NONHUMAN; OBESITY; PARKINSON DISEASE; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PROLACTINOMA; REVIEW; THORAX PAIN; TREATMENT DURATION; VALVULAR HEART DISEASE; VASCULAR HEADACHE;

ANIMALS; ECHOCARDIOGRAPHY, DOPPLER, COLOR; FEMALE; FENFLURAMINE; HEART VALVE DISEASES; HUMANS; MALE; PHARMACEUTICAL PREPARATIONS; RISK FACTORS; SEROTONIN AGENTS;

EID: 67650361216     PISSN: 15252167     EISSN: 15322114     Source Type: Journal    
DOI: 10.1093/ejechocard/jep023     Document Type: Review

References (118)

1. Graham JR, Suby HI, LeCompte PR, Sadowsky NL. Fibrotic disorders associated with methysergide therapy for headache. N Engl J Med 1966;274:359-68.
2. Pfitzenmeyer P, Foucher P, Dennewald G, Chevalon B, Debieuvre D, Bensa P et al. Pleuropulmonary changes induced by ergoline drugs. Eur Respir J 1996;9:1013-9.
3. Danoff SK, Grasso ME, Terry PB, Flynn JA. Pleuropulmonary disease due to pergolide use for restless legs syndrome. Chest 2001;120:313-6.
4. Dhawan V, Medcalf P, Stegie F, Jackson G, Basu S, Luce P et al. Retrospective evaluation of cardio-pulmonary fibrotic side effects in symptomatic patients from a group of 234 Parkinson's disease patients treated with cabergoline. J Neural Trans 2005;112:661-8.
5. Wilke A, Hesse H, Hufnagel G, Maisch B. Mitral, aortic and tricuspid valvular heart disease associated with ergotamine therapy for migraine. Eur Heart J 1997;18:701.
6. Silberstein SD. Methysergide. Cephalalgia 1998;18:421-35.
7. Hendrikx M, Van Dorpe J, Flameng W, Daenen W. Aortic and mitral valve disease induced by ergotamine therapy for migraine: a case report and review of the literature. J Heart Valve Dis 1996;5:235-7.
8. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD et al. Valvular heart disease associated with fenfluraminephentermine. N Engl J Med 1997;337:581-8.
9. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations, November 1997. MMWR Morb Mortal Wkly Rep 1997;46:1061-6.
10. Sachdev M, Miller WC, Ryan T, Jollis JG. Effect of fenfluraminederivative diet pills on cardiac valves: a meta-analysis of observational studies. Am Heart J 2002;144:1065-73.
11. Hopkins PN, Polukoff GI. Risk of valvular heart disease associated with use of fenfluramine. BMC Cardiovasc Disord 2003;3:5.
12. Roldan CA, Gill EA, Shively BK. Prevalence and diagnostic value of precordial murmurs for valvular regurgitation in obese patients treated with dexfenfluramine. Am J Cardiol 2000;86:535-9.
13. Weissman NJ, Tighe JF Jr, Gottdiener JS, Gwynne JT. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group. N Engl J Med 1998;339:725-32.
14. Pritchett AM, Morrison JF, Edwards WD, Schaff HV, Connolly HM, Espinosa RE. Valvular heart disease in patients taking pergolide. Mayo Clin Proc 2002;77:1280-6.
15. Van Camp G, Flamez A, Cosyns B, Goldstein J, Perdaens C, Schoors D. Heart valvular disease in patients with Parkinson's disease treated with high-dose pergolide. Neurology 2003;61:859-61.
16. Van Camp G, Flamez A, Cosyns B, Weytjens C, Muyldermans L, Van Zandijcke M et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004;363: 1179-83.
17. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007;356: 29-38.
18. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007;356:39-46.
19. Horvath J, Fross RD, Kleiner-Fisman G, Lerch R, Stalder H, Liaudat S et al. Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord 2004;19:656-62.
20. Tellier P. Fenfluramines, idiopathic pulmonary primary hypertension and cardiac valve disorders: facts and artifacts. Ann Med Interne (Paris) 2001;152:429-36.
21. Loke YK, Derry S, Pritchard-Copley A. Appetite suppressants and valvular heart disease - a systematic review. BMC Clin Pharmacol 2002;2:6.
22. Jick H, Vasilakis C, Weinrauch LA, Meier CR, Jick SS, Derby LE. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med 1998;339:719-24.
23. Khan MA, Herzog CA, St Peter JV, Hartley GG, Madlon-Kay R, Dick CD et al. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetitesuppressant drugs. New Eng J Med 1998;339:713-8.
24. Droogmans S, Franken PR, Garbar C, Weytjens C, Cosyns B, Lahoutte T et al. In vivo model of drug-induced valvular heart disease in rats: pergolide-induced valvular heart disease demonstrated with echocardiography and correlation with pathology. Eur Heart J 2007;28:2156-62.
25. Gustafsson BI, Hauso O, Drozdov I, Kidd M, Modlin IM. Carcinoid heart disease. Int J Cardiol 2008;129:318-24.
26. Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ et al. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 2000;102:2836-41.
27. Gustafsson BI, Tommeras K, Nordrum I, Loennechen JP, Brunsvik A, Solligard E et al. Long-term serotonin administration induces heart valve disease in rats. Circulation 2005;111:1517-22.
28. Mekontso-Dessap A, Brouri F, Pascal O, Lechat P, Hanoun N, Lanfumey L et al. Deficiency of the 5-hydroxytryptamine transporter gene leads to cardiac fibrosis and valvulopathy in mice. Circulation 2006;113:81-9.
29. Pellikka PA, Tajik AJ, Khandheria BK, Seward JB, Callahan JA, Pitot HC et al. Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients. Circulation 1993;87:1188-96.
30. Bhattacharyya S, Davar J, Dreyfus G, Caplin ME. Carcinoid heart disease. Circulation 2007;116:2860-5.
31. Roldan CA, Gelgand EA, Decker P, Prasad A, Shively BK. Morphology of anorexigen-associated valve disease by transthoracic and transesophageal echocardiography. Am J Cardiol 2002;90:1269-73.
32. Zolkowska D, Rothman RB, Baumann MH. Amphetamine analogs increase plasma serotonin: implications for cardiac and pulmonary disease. J Pharmacol Exp Ther 2006;318:604-10.
33. Zolkowska D, Baumann MH, Rothman RB. Chronic fenfluramine administration increases plasma serotonin (5-hydroxytryptamine) to nontoxic levels. J Pharmacol Exp Ther 2008;324:791-7.
34. Elangbam CS, Job LE, Zadrozny LM, Barton JC, Yoon LW, Gates LD et al. 5-hydroxytryptamine (5HT)-induced valvulopathy: compositional valvular alterations are associated with 5HT2B receptor and 5HT transporter transcript changes in Sprague-Dawley rats. Exp Toxicol Pathol 2008;60: 253-62.
35. Setola V, Dukat M, Glennon RA, Roth BL. Molecular determinants for the interaction of the valvulopathic anorexigen norfenfluramine with the 5-HT2B receptor. Mol Pharmacol 2005;68:20-33.
36. Rajamannan NM, Caplice N, Anthikad F, Sebo TJ, Orszulak TA, Edwards WD et al. Cell proliferation in carcinoid valve disease: a mechanism for serotonin effects. J Heart Valve Dis 2001;10: 827-31.
37. Jian B, Xu J, Connolly J, Savani RC, Narula N, Liang B et al. Serotonin mechanisms in heart valve disease I: serotonin-induced up-regulation of transforming growth factor-beta1 via G-protein signal transduction in aortic valve interstitial cells. Am J Pathol 2002;161:2111-21.
38. Jahnichen S, Horowski R, Pertz HH. Agonism at 5-HT2B receptors is not a class effect of the ergolines. Eur J Pharmacol 2005;513:225-8.
39. Setola V, Roth BL. Screening the receptorome reveals molecular targets responsible for drug-induced side effects: focus on 'fen-phen'. Expert Opin Drug Metab Toxicol 2005;1:377-87.
40. McDonald PC, Wilson JE, Gao M, McNeill S, Spinelli JJ, Williams OD et al. Quantitative analysis of human heart valves: does anorexigen exposure produce a distinctive morphological lesion? Cardiovasc Pathol 2002;11: 251-62.
41. Singh JP, Evans JC, Levy D, Larson MG, Freed LA, Fuller DL et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol 1999;83:897-902.
42. Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol 2007;6:826-9.
43. Bana DS, MacNeal PS, LeCompte PM, Shah Y, Graham JR. Cardiac murmurs and endocardial fibrosis associated with methysergide therapy. Am Heart J 1974;88:640-55.
44. Mason JW, Billingham ME, Friedman JP. Methysergide-induced heart disease: a case of multivalvular and myocardial fibrosis. Circulation 1977;56:889-90.
45. Hauck AJ, Edwards WD, Danielson GK, Mullany CJ, Bresnahan DR. Mitral and aortic valve disease associated with ergotamine therapy for migraine. Report of two cases and review of literature. Arch Pathol Lab Med 1990;114:62-4.
46. Redfield MM, Nicholson WJ, Edwards WD, Tajik AJ. Valve disease associated with ergot alkaloid use: echocardiographic and pathologic correlations. Ann Intern Med 1992;117:50-2.
47. Wee CC, Phillips RS, Aurigemma G, Erban S, Kriegel G, Riley M et al. Risk for valvular heart disease among users of fenfluramine and dexfenflura mine who underwent echocardiography before use of medication. Ann Intern Med 1998;129:870-4.
48. Kancherla MK, Salti HI, Mulderink TA, Parker M, Bonow RO, Mehlman DJ. Echocardiographic prevalence of mitral and/or aortic regurgitation in patients exposed to either fenfluramine-phentermine combination or to dexfenfluramine. Am J Cardiol 1999;84:1335-8.
49. Gardin JM, Schumacher D, Constantine G, Davis KD, Leung C, Reid CL. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. JAMA 2000;283: 1703-9.
50. Dahl CF, Allen MR, Urie PM, Hopkins PN. Valvular regurgitation and surgery associated with fenfluramine use: an analysis of 5743 individuals. BMC Med 2008;6:34.
51. Peralta C, Wolf E, Alber H, Seppi K, Muller S, Bosch S et al. Valvular heart disease in Parkinson's disease vs. controls: an echocardiographic study. Mov Disord 2006;21:1109-13.
52. Junghanns S, Fuhrmann JT, Simonis G, Oelwein C, Koch R, Strasser RH et al. Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study. Mov Disord 2007;22:234-8.
53. Yamamoto M, Uesugi T, Nakayama T. Dopamine agonists and cardiac valvulopathy in Parkinson disease - a case-control study. Neurology 2006; 67:1225-9.
54. Dewey RB 2nd, Reimold SC, O'suilleabhain PE. Cardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson disease. Arch Neurol 2007;64:377-80.
55. Kim JY, Chung EJ, Park SW, Lee WY. Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists. Mov Disord 2006;21:1261-4.
56. Corvol JC, Anzouan-Kacou JB, Fauveau E, Bonnet AM, Lebrun-Vignes B, Girault C et al. Heart valve regurgitation, pergolide use, and parkinson disease: an observational study and meta-analysis. Arch Neurol 2007; 64:1721-6.
57. Simonis G, Fuhrmann JT, Strasser RH. Meta-analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists. Mov Disord 2007;22:1936-42.
58. Kars M, Pereira AM, Bax JJ, Romijn JA. Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required. Eur J Endocrinol 2008;159:363-7.
59. Colao A, Galderisi M, Di Sarno A, Pardo M, Gaccione M, D'Andrea M et al. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J Clin Endocrinol Metab 2008;93:3777-84.
60. Kars M, Delgado V, Holman ER, Feelders RA, Smit JWA, Romijn JA et al. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. J Clin Endocrinol Metab 2008;93:3348-56.
61. Wakil A, Rigby AS, Clark AL, Kallvikbacka-Bennett A, Atkin SL. Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. Eur J Endocrinol 2008;159:R11- R14.
62. Tan LC, Ng KK, Au WL, Lee RK, Chan YH, Tan NC. Bromocriptine use and the risk of valvular heart disease. Mov Disord 2009;24:344-9.
63. Setola V, Hufeisen SJ, Grande-Allen KJ, Vesely I, Glennon RA, Blough B et al. 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy') induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol 2003;63:1223-9.
64. Droogmans S, Cosyns B, D'Haenen H, Creeten E, Weytjens C, Franken PR et al. Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease. Am J Cardiol 2007;100:1442-5.
65. Noize P, Sauer M, Bruneval P, Moreau M, Pathak A, Bagheri H et al. Valvular heart disease in a patient taking benfluorex. Fundam Clin Pharmacol 2006;20:577-8.
66. Rafel Ribera J, Casanas Munoz R, Anguera Ferrando N, Batalla Sahun N, Castro Cels A, Pujadas Capmany R. Valvular heart disease associated with benfluorex. Rev Esp Cardiol 2003;56:215-6.
67. Mast ST, Gersing KR, Anstrom KJ, Krishnan KR, Califf RM, Jollis JG. Association between selective serotonin-reuptake inhibitor therapy and heart valve regurgitation. Am J Cardiol 2001;87:989-93.
68. Rothman RB, Zolkowska D, Baumann MH. Serotonin (5-HT) transporter ligands affect plasma 5-HT in rats. Ann N YAcad Sci 2008;1139:268-84.
69. Roth BL. Drugs and valvular heart disease. N Engl J Med 2007;356:6-9.
70. Li R, Serdula MK, Williamson DF, Bowman BA, Graham DJ, Green L. Dose-effect of fenfluramine use on the severity of valvular heart disease among fen-phen patients with valvulopathy. Int J Obes 1999; 23:926-8.
71. Jollis JG, Landolfo CK, Kisslo J, Constantine GD, Davis KD, Ryan T. Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities. Circulation 2000; 101:2071-7.
72. Lepor NE, Gross SB, Daley WL, Samuels BA, Rizzo MJ, Luko SP et al. Dose and duration of fenfluramine-phentermine therapy impacts the risk of significant valvular heart disease. Am J Cardiol 2000;86:107-10.
73. Ruzicka E, Linkova H, Penicka M, Ulmanova O, Novakova L, Roth J. Low incidence of restrictive valvulopathy in patients with Parkinson's disease on moderate dose of pergolide. J Neurol 2007;254:1575-8.
74. Muraki M, Mikami T, Kitaguchi M, Sugawara T, Isonishi K, Kaneko S et al. Effects of low-dose pergolide therapy on cardiac valves in patients with Parkinson's disease. J Cardiol 2005;46:221-7.
75. Yamashiro K, Komine-Kobayashi M, Hatano T, Urabe T, Mochizuki H, Hattori N et al. The frequency of cardiac valvular regurgitation in Parkinson's disease. Mov Disord 2008;23:935-41.
76. Worthington A, Thomas L. Valvular heart disease associated with taking low-dose pergolide for restless legs syndrome. Eur J Echocardiogr 2008; 9:828-30.
77. Droogmans S, Cosyns B, Van Camp G. Pergolide and valvular heart disease: the lower the better? Eur J Echocardiogr 2008;9:717-8.
78. Chung EJ, Yoon WT, Kim JY, Lee WY. Valvular heart disease in a patient with Parkinson's disease treated with a low daily dose and a low cumulative dose of pergolide. Mov Disord 2006;21:586-7.
79. Shively BK, Roldan CA, Gill EA, Najarian T, Loar SB. Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine. Circulation 1999;100:2161-7.
80. Oeda T, Masaki M, Yamamoto K, Mizuta E, Kitagawa N, Isono Tet al. High risk factors for valvular heart disease from dopamine agonists in patients with Parkinson's disease. J Neural Transm 2009;116:171-8.
81. Hensrud DD, Connolly HM, Grogan M, Miller FA, Bailey KR, Jensen MD. Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine. Mayo Clin Proc 1999;74:1191-7.
82. Mast ST, Jollis JG, Ryan T, Anstrom KJ, Crary JL. The progression of fenfluramine-associated valvular heart disease assessed by echocardiography. Ann Intern Med 2001;134:261-6.
83. Weissman NJ, Panza JA, Tighe JF, Gwynne JT. Natural history of valvular regurgitation 1 year after discontinuation of dexfenfluramine therapy. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001;134:267-73.
84. Gardin JM, Weissman NJ, Leung C, Panza JA, Fernicola D, Davis KD et al. Clinical and echocardiographic follow-up of patients previously treated with dexfenfluramine or phentermine/fenfluramine. JAMA 2001;286: 2011-4.
85. Unger P, Nortier JL, Martinez MCM, Plein D, Vandenbossche JL, Vereerstracten P et al. High prevalence of fenfluramine-related aortic regurgitation in women with end-stage renal disease secondary to Chinese herb nephropathy. Nephrol Dial Transplant 2003;18:906-10.
86. Baseman DG, O'suilleabhain PE, Reimold SC, Laskar SR, Baseman JG, Dewey RB Jr. Pergolide use in Parkinson disease is associated with cardiac valve regurgitation. Neurology 2004;63:301-4.
87. Flowers CM, Racoosin JA, Lu SL, Beitz JG. The US Food and Drug Administration's registry of patients with pergolide-associated valvular heart disease. Mayo Clin Proc 2003;78:730-1.
88. Dupuy D, Lesbre JP, Gerard P, Andrejak M, Godefroy O. Valvular heart disease in patients with Parkinson's disease treated with pergolide. Course following treatment modifications. J Neurol 2008;255:1045-8.
89. Elangbam CS, Wehe JG, Barton JC, Krull DL, Nyska A, Crabbs T et al. Evaluation of glycosaminoglycans content and 5-hydroxytryptamine 2B receptor in the heart valves of Sprague-Dawley rats with spontaneous mitral valvulopathy - a possible exacerbation by dl-amphetamine sulfate in Fischer 344 rats? Exp Toxicol Pathol 2006;58:89-99.
90. Lledo A, Dellva MA, Strombom IM, Wilkie JL, Jungemann ME, Royer MG et al. Awareness of potential valvulopathy risk with pergolide and changes in clinical practice after label change: a survey among European neurologists. Eur J Neurol 2007;14:644-9.
91. Markowitz JS, DeVane CL, Pestreich LK, Patrick KS, Muniz R. A comprehensive in vitro screening of d-, l-, and dl-threo-methylphenidate: an exploratory study. J Child Adolesc Psychopharmacol 2006;16:687-98.
92. Flaherty KR, Bates JR. Mitral regurgitation caused by chronic ergotamine use. Am Heart J 1996;131:603-6.
93. Creutzig A. Ergotamine-induced heart valve fibrosis and coronary microangiopathy?. Dtsch Med Wochenschr 1992;117:1736.
94. Joseph T, Tam SK, Kamat BR, Mangion JR. Successful repair of aortic and mitral incompetence induced by methylsergide maleate: confirmation by intraoperative transesophageal echocardiography. Echocardiography 2003;20:283-7.
95. Serratrice J, Disdier P, Habib G, Viallet F, Weiller PJ. Fibrotic valvular heart disease subsequent to bromocriptine treatment. Cardiol Rev 2002;10:334-6.
96. Ruzicka E, Linkova H, Penicka M, Roth J, Ulmanova O, Novakova L et al. Valvular heart disease is rare in Parkinson's disease patients treated with pergolide. Eur J Neurol 2006;13:82.
97. Schlesinger I, Katz M, Aharon-Perez J, Badarny S, Bloch I, Gross B et al. Frequency of restrictive valvular heart disease in patients with Parkinson's disease treated with pergolide, an ergot-derived anti-parkinsonian drug: a case-control echocardiographic study. J Neurol 2005;252:30.
98. Scozzafava J, Takahashi J, Johnston W, Puttagunta L, Martin WW. Valvular heart disease in pergolide-treated Parkinson's disease. Can J Neurol Sci 2006;33:111-3.
99. Waller EA, Kaplan J, Heckman MG. Valvular heart disease in patients taking pergolide. Mayo Clin Proc 2005;80:1016-20.
100. Zadikoff C, Duong-Hua M, Sykora K, Marras C, Lang A, Rochon P. Pergolide associated cardiac valvulopathy based on Ontario administrative data. Can J Neurol Sci 2008;35:173-8.
101. Zadikoff C, Rochon P, Lang A. Cardiac valvulopathy associated with pergolide use. Can J Neurol Sci 2006;33:27-33.
102. Pinero A, Marcos-Alberca P, Fortes J. Cabergoline-related severe restrictive mitral regurgitation. N Engl J Med 2005;353:1976-7.
103. Lancellotti P, Livadariu E, Markov M, Daly AF, Burlacu MC, Betea D et al. Cabergoline and the risk of valvular lesions in endocrine disease. Eur J Endocrinol 2008;159:1-5.
104. Bogazzi F, Buralli S, Manetti L, Raffaelli V, Cigni T, Lombardi M et al. Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia. Int J Clin Pract 2008;62:1864-9.
105. Vallette S, Serri K, Rivera J, Santagata P, Delorme S, Garfield N et al. Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary, DOI: 10.1007/ s11102-008-0134-2.
106. Herring N, Szmigielski C, Becher H, Karavitaki N, Wass JA. Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clin Endocrinol (Oxf) 2009;70:104-8.
107. Adams C, Cohen A. Appetite-suppressant drugs and heart valve abnormalities. Arch Mal Coeur Vaiss 1999;92:1213-9.
108. Biswas SS, Donovan CL, Forbess JM, Royal SH, Landolfo KP. Valve replacement for appetite suppressant-induced valvular heart disease. Ann Thoracic Surg 1999;67:1819-22.
109. Burger AJ, Sherman HB, Charlamb MJ, Kim J, Asinas LA, Flickner SR et al. Low prevalence of valvular heart disease in 226 phenterminefenfluramine protocol subjects prospectively followed for up to 30 months. J Am Coll Cardiol 1999;34:1153-8.
110. Cannistra LB, Cannistra AJ. Regression of multivalvular regurgitation after the cessation of fenfluramine and phentermine treatment. N Engl J Med 1998;339:771.
111. Davidoff R, McTiernan A, Constantine G, Davis KD, Balady GJ, Mendes LA et al. Echocardiographic examination of women previously treated with fenfluramine - long-term follow-up of a randomized, double-blind, placebo-controlled trial. Arch Intern Med 2001;161:1429-36.
112. Fitzgerald LW, Burn TC, Brown BS, Patterson JP, Corjay MH, Valentine PA et al. Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 2000;57: 75-81.
113. Fowles RE, Cloward TV, Yowell RL. Endocardial fibrosis associated with fenfluramine-phentermine. N Engl J Med 1998;338:1316.
114. Greffe G, Chalabreysse L, Mouly-Bertin C, Lantelme P, Thivolet F, Aulagner G et al. Valvular heart disease associated with fenfluramine detected 7 years after discontinuation of treatment. Ann Thorac Surg 2007;83:1541-3.
115. Volmar KE, Hutchins GM. Aortic and mitral fenfluramine-phentermine valvulopathy in 64 patients treated with anorectic agents. Arch Pathol Lab Med 2001;125:1555-61.
116. Weissman NJ, Tighe JF, Gottdiener JS, Gwynne JT. Prevalence of valvular-regurgitation associated with dexfenfluramine three to five months after discontinuation of treatment. J Am Coll Cardiol 1999; 34:2088-95.
117. Vanherweghem JL. Association of valvular heart disease with Chineseherb nephropathy. Lancet 1997;350:1858.
118. Milroy CM, Clark JC, Forrest AR. Pathology of deaths associated with 'ecstasy' and 'eve' misuse. J Clin Pathol 1996;49:149-53.